enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company aiming to mainstream gene-based immunotherapy by advancing non-viral treatments that can be delivered locally to the site of disease—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. Founded in Canada, with a United States headquarters located in Boston, we are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes.
To learn more about enGene visit our website: enGene.com.
We are currently enrolling select patients with NMIBC in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region. For more information, please visit TheLegendStudy.com.
Company Details
- Employees
- 131
- Founded
- -
- Address
- 99 High Street, Boston,massachusetts 02110,united States
- Phone
- 604-221-4362
- in****@****inc.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://engene.com/
- Keywords
- gene-based immunotherapy, urology, oncology, NMIBC, non-muscle invasive bladder cancer, bladder cancer, DNA, RNA, genetic medicines, mucosal tissues, non-viral gene therapy, drug development.
- HQ
- Boston, Massachusetts
Engene Questions
Engene's helpline number is 604-221-4362
Engene's website is https://engene.com/
Engene's LinkedIn profile is https://www.linkedin.com/company/engene
Engene has
131 employees.
View email and phone details for 131
employees at Engene.
Engene's industry is
Biotechnology Research
Engene's top competitors are
Taalas,
Borealis Biosciences, Inc.,
Clearsky Global,
Brim Financial,
Waabi,
Ideogram,
Cohere,
Flo Ev Charging,
Ugowork,
Elective.
Engene's support email address is info@engeneinc.com
Engene's categories are Biotechnology Research
Engene's founding year is 1999
